Not Yet RecruitingNot Applicable

Early Detection of COPD Exacerbations Using Home Monitoring Device

United States30 participantsStarted 2026-05

Plain-language summary

The goal of this observational study is to evaluate the safety and effectiveness of a home-monitoring device (RespirAI) in the early detection of COPD exacerbations in adults (age \>21) with physician-diagnosed COPD who are at high risk for exacerbations. The study will collect data from participants with COPD that will be analyzed using an AI-based algorithm to predict exacerbation events. The device's predictions will then be compared against clinically documented exacerbations to assess detection accuracy.

Who can participate

Age range

21 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \>21 years. * Physician-diagnosed COPD at least 6 months prior to screening visit. * Two or more moderate COPD exacerbations in the past 6 months or 1 severe exacerbation during the past 6 months. * Free of exacerbation for 1 month before enrollment. Exclusion Criteria: * Unable or willing to sign an informed consent. * Unable to complete the 6-minute walk test due to physical or mental health conditions. * Patients with cardiac pacemaker, defibrillators, or other implanted electronic devices. * Pregnancy * Study clinician determines that the patient is unable or unwilling to comply with all study procedures.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Sensitivity

Timeframe: 6 months

False alam rate

Timeframe: 6 months

Trial details

NCT IDNCT07554352

SponsorRespirAI US Inc

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-05

Contact for this trial

Tamar Sobol

(617) 615-6799‬ info@respriai.com

View on ClinicalTrials.gov More COPD Exacerbation trials